Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemiaMaxim Norkin, John R. Wingard, Robert Hromas et al.|Blood Cancer Journal|2017Cited by 26
Effect of melphalan 140 mg/m<sup>2</sup> vs 200 mg/m<sup>2</sup> on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation—a single center experienceLakshmikanth Katragadda, Jan S. Moreb, Lindsay McCullough et al.|Clinical Transplantation|2016Cited by 19
A new model to predict remission status in AML patients based on day 14 bone marrow biopsyMaxim Norkin, Christopher R. Cogle, Myron Chang et al.|Leukemia Research|2016Cited by 14
A New Model to Predict Remission Status in Acute Myeloid Leukemia (AML) Patients Based on Day 14 Bone Marrow (D14 BM) BiopsyMaxim Norkin, Christopher R. Cogle, Myron Chang et al.|Blood|2015Cited by 0
Minimal Residual Disease (MRD) By Either Flow Cytometry or Cytogenetics Prior to an Allogeneic Hematopoietic Cell Transplant (allo-HCT) Predicts Poor Acute Myeloid Leukemia (AML) OutcomesLakshmikanth Katragadda, John R. Wingard, Maxim Norkin et al.|Blood|2015Cited by 0